Related Experiment Video
Updated: Jan 31, 2026

Actin Co-Sedimentation Assay; for the Analysis of Protein Binding to F-Actin
Published on: March 28, 2008
Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors
G Mantovani1, D Treppiedi1, E Giardino1
1Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Abstract:
Although generally benign, pituitary tumors are frequently locally invasive, with reduced success of neurosurgery and unresponsive to pharmacological treatment with somatostatin or dopamine analogues. The molecular basis of the different biological behavior of pituitary tumors are still poorly identified, but a body of work now suggests that the activity of specific cytoskeleton proteins is a key factor regulating both the invasiveness and drug resistance of these tumors. This review recapitulates the experimental evidence supporting a role for the actin-binding protein filamin A (FLNA) in the regulation of somatostatin and dopamine receptors expression and signaling in pituitary tumors, thus in determining the responsiveness to currently used drugs, somatostatin analogues and dopamine receptor type 2 agonists. Regarding the regulation of invasive behavior of pituitary tumoral cells, we bring evidence to the role of the actin-severing protein cofilin, whose activation status may be modulated by dopaminergic and somatostatinergic drugs, through FLNA involvement. Molecular mechanisms involved in the regulation of FLNA expression and function in pituitary tumors will also be discussed.
Insights
Pituitary tumor cells
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Pituitary tumors often exhibit local invasiveness and resistance to current treatments.
- The molecular mechanisms underlying pituitary tumor behavior are not fully understood.
- Cytoskeleton protein activity is increasingly recognized as a key factor in tumor invasiveness and drug resistance.
Purpose of the Study:
- To review evidence on the role of filamin A (FLNA) in pituitary tumor drug responsiveness.
- To explore the involvement of cofilin in regulating pituitary tumor cell invasiveness.
- To discuss the molecular regulation of FLNA in pituitary tumors.
Main Methods:
- Literature review of experimental evidence.
- Analysis of the role of actin-binding proteins in pituitary tumor biology.
- Discussion of molecular mechanisms regulating protein expression and function.
Main Results:
- Filamin A (FLNA) influences somatostatin and dopamine receptor expression and signaling, affecting drug response.
- Cofilin activation status, modulated by FLNA, impacts pituitary tumor cell invasiveness.
- Dopaminergic and somatostatinergic drugs may modulate cofilin activity via FLNA.
Conclusions:
- FLNA is a critical regulator of both drug responsiveness and invasiveness in pituitary tumors.
- Targeting cytoskeleton proteins like FLNA and cofilin may offer new therapeutic strategies.
- Further research into FLNA regulation is needed for improved pituitary tumor treatment.
Related Concept Videos
Hypothalamic-Pituitary Axis
Hormones of the Pituitary Gland
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
Polarity of the Cytoskeleton
The Pituitary Gland
Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The Equilibrium Binding Constant and Binding Strength

